Cause analysis and countermeasures of extravasation of non-chemotherapeutic drugs

NI Lefeng; GONG Weijuan; LIU Lin; YAN Renhui

doi:10.7619/jcmp.20212480

Journal of Clinical Medicine in Practice > 2022 > 26(6): 145-148. > DOI: 10.7619/jcmp.20212480

NI Lefeng, GONG Weijuan, LIU Lin, YAN Renhui. Cause analysis and countermeasures of extravasation of non-chemotherapeutic drugs[J]. Journal of Clinical Medicine in Practice, 2022, 26(6): 145-148. DOI: 10.7619/jcmp.20212480

Citation:

PDF (635 KB)

Cause analysis and countermeasures of extravasation of non-chemotherapeutic drugs

1.
School of Nursing of Yangzhou University, Yangzhou, Jiangsu, 225000
2.
Hematology Department, Xinghua People's Hospital Affiliated to Yangzhou University, Xinghua, Jiangsu, 225700
3.
Nursing Department, Xinghua People's Hospital Affiliated to Yangzhou University, Xinghua, Jiangsu, 225700

More Information

Received Date: November 20, 2021
Available Online: April 08, 2022
Published Date: March 27, 2022

Graphical Abstract

Abstract

Abstract

Based on the related factors of non-chemotherapy drug extravasation, mechanism of tissue injury induced by extravasation, and prevention and treatment methods, this paper summarized the research progress of non-chemotherapy drug extravasation protection, proposed the corresponding management norms and training mechanism of non-chemotherapy drugs, so that clinical nurses can master the management methods of non-chemotherapy drug extravasation.
- non-chemotherapy drugs,
- drug extravasation,
- hypertonic drugs,
- acid and basic drugs,
- vasopressor drugs,
- nursing

FullText(HTML)

References (35)

References

[1]	国家卫生计生委. 静脉治疗护理技术操作规范[J]. 中国护理管理, 2014, 14(1): 1-4.
[2]	ONG J, VAN GERPEN R. Recommendations for management of noncytotoxic vesicant extravasations[J]. J Infus Nurs, 2020, 43(6): 319-343. doi: 10.1097/NAN.0000000000000392
[3]	熊恩平, 邓洁. 静脉腐蚀性药物输注外渗风险评估体系的构建[J]. 护理研究, 2017, 31(32): 4082-4086. doi: 10.3969/j.issn.1009-6493.2017.32.013
[4]	中华护理学会. 中华护理学会关于发布《成人癌性疼痛护理》等9项团体标准的公告[EB/OL]. (2019-11-10)[2022-05-15]. http://www.zhhlxh.org.cn/cnaWebcn/article/2130.
[5]	BOYAR V, COLLEEN G. Reducing Peripheral Intravenous Catheter Extravasation in Neonates[J]. Journal of Wound, Ostomy & Continence Nursing, 2021, 48(1): 31-38.
[6]	VERYKIOU S, ALJEFRI K, GOPEE H, et al. Cutaneous manifestations of phosphate solution extravasation[J]. Clin Exp Dermatol, 2018, 43(1): 42-45. doi: 10.1111/ced.13233
[7]	GÜLÇIN ÖZALP GERÇEKER, KAHRAMAN AYŞE, YARDIMCI FIGEN, et al. Infiltration and extravasation in pediatric patients: A prevalence study in a children's hospital[J]. The Journal of Vascular Access, 2018, 19(3): 266-271. doi: 10.1177/1129729817747532
[8]	VARACALLO M, SHIREY L, KAVURI V, et al. Acute compartment syndrome of the hand secondary to propofol extravasation[J]. J Clin Anesth, 2018, 47: 1-2. doi: 10.1016/j.jclinane.2018.01.020
[9]	GORSKI L A, STRANZ M, COOK L S, et al. Development of an evidence-based list of noncytotoxic vesicant medications and solutions[J]. J Infus Nurs, 2017, 40(1): 26-40. doi: 10.1097/NAN.0000000000000202
[10]	DAVID V, CHRISTOU N, ETIENNE P, et al. Extravasation of noncytotoxic drugs[J]. Ann Pharmacother, 2020, 54(8): 804-814. doi: 10.1177/1060028020903406
[11]	王建新, 苏金娜, 李云涛, 等. 静脉输液港输液外渗的原因分析及对策[J]. 护理学杂志, 2017, 32(3): 46-48. doi: 10.3870/j.issn.1001-4152.2017.03.046
[12]	郭书芳. 循证护理对预防静脉输液患儿液体外渗的效果评价[J]. 首都食品与医药, 2018, 25(5): 61-61. doi: 10.3969/j.issn.1005-8257.2018.05.055
[13]	MAX LITTLE, DUPRÉSOPHIE, WORMALD JUSTIN-CONRAD-ROSEN, et al. Surgical intervention for paediatric infusion-related extravasation injury: a systematic review[J]. BMJ Open, 2020, 10(8): e34950.
[14]	REYNOLDS P M, MACLAREN R, MUELLER S W, et al. Management of extravasation injuries: a focused evaluation of noncytotoxic medications[J]. Pharmacotherapy, 2014, 34(6): 617-632. doi: 10.1002/phar.1396
[15]	ZENATI N, KHOURI C, SCHWEBEL C, et al. Skin necrosis and calcifications after extravasation of vancomycin: a localised form of calciphylaxis[J]. J Wound Care, 2021, 30(5): 390-393. doi: 10.12968/jowc.2021.30.5.390
[16]	洪中, 李远珍, 殷勤. 血管活性药物外渗的护理研究进展[J]. 护士进修杂志, 2019, 34(18): 1655-1657.
[17]	NICKEL B. Peripheral intravenous access: applying infusion therapy standards of practice to improve patient safety[J]. Crit Care Nurse, 2019, 39(1): 61-71. doi: 10.4037/ccn2019790
[18]	张玉洁, 崔妮, 赵晓虹, 等. 发疱类化疗药物致儿童静脉外渗防护研究进展[J]. 护理研究, 2017, 31(10): 1174-1176. doi: 10.3969/j.issn.1009-6493.2017.10.007
[19]	KIMMEL J, FLEMING P, CUELLAR S, et al. Pharmacological management of anticancer agent extravasation: a single institutional guideline[J]. J Oncol Pharm Pract, 2018, 24(2): 129-138. doi: 10.1177/1078155217690924
[20]	黄东婧. 静脉输液外渗原因及护理对策[J]. 当代护士: 上旬刊, 2018, 25(5): 9-11. doi: 10.3969/j.issn.1006-6411.2018.05.005
[21]	李春燕. 美国INS2016版《输液治疗实践标准》要点解读[J]. 中国护理管理, 2017, 17(2): 150-153. doi: 10.3969/j.issn.1672-1756.2017.02.002
[22]	CLARK E, BARBARA-K G, JOHN H, et al. Reducing Risk of Harm From Extravasation[J]. Journal of Infusion Nursing, 2013, 36(1): 37-45. doi: 10.1097/NAN.0b013e3182798844
[23]	陈尚学, 徐静. 静脉输液外渗的原因分析及防护对策[J]. 西南医科大学学报, 2020, 43(1): 90-93. doi: 10.3969/j.issn.2096-3351.2020.01.021
[24]	赵广慧, 林倩倩. 静脉输液外渗相关因素分析[J]. 中国烧伤创疡杂志, 2018, 30(5): 361-365. doi: 10.3969/j.issn.1001-0726.2018.05.011
[25]	丁伟伟. 药物因素静脉输液外渗的护理——评《医学化学》[J]. 化学工程, 2020, 48(10): 6-7. doi: 10.3969/j.issn.1005-9954.2020.10.002
[26]	边雪梅, 孙敏, 阙建兰, 等. 1例氯化钙外渗致皮下硬结患者的中西医结合护理[J]. 护理学报, 2018, 25(21): 67-68.
[27]	KREIDIEH F Y, MOUKADEM H A, EL SAGHIR N S. Overview, prevention and management of chemotherapy extravasation[J]. World J Clin Oncol, 2016, 7(1): 87-97. doi: 10.5306/wjco.v7.i1.87
[28]	ALEXANDROU E, GILLIAN R B, PETER J C, et al. Use of Short Peripheral Intravenous Catheters: Characteristics, Management, and Outcomes Worldwide[J]. Journal of Hospital Medicine, 2018, 13(5): 223-229.
[29]	杨洪华, 刘万里, 贺连香, 等. 降低留置针药物外渗的循证护理实践[J]. 护士进修杂志, 2020, 35(19): 1734-1738.
[30]	LEWIS T, MERCHAN C, ALTSHULER D, et al. Safety of the peripheral administration of vasopressor agents[J]. J Intensive Care Med, 2019, 34(1): 26-33. doi: 10.1177/0885066616686035
[31]	CHAN K M, CHAU J P C, CHOI K C, et al. Clinical practice guideline on the prevention and management of neonatal extravasation injury: a before-and-after study design[J]. BMC Pediatr, 2020, 20(1): 445. doi: 10.1186/s12887-020-02346-9
[32]	KIM J T, PARK J Y, LEE H J, et al. Guidelines for the management of extravasation[J]. J Educ Eval Health Prof, 2020, 17: 21. doi: 10.3352/jeehp.2020.17.21
[33]	WEBER G C, BUHREN B A, SCHRUMPF H, et al. Clinical applications of hyaluronidase[J]. Adv Exp Med Biol, 2019, 1148: 255-277.
[34]	ANN LE, PATEL SAMIT. Extravasation of Noncytotoxic Drugs[J]. Annals of Pharmacotherapy, 2014, 48(7): 870-886. doi: 10.1177/1060028014527820
[35]	PLUM M, OUSSAYMA M. Alternative Pharmacological Management of Vasopressor Extravasation in the Absence of Phentolamine[J]. P & T (Lawrenceville, N. J. ), 2017, 42(9): 581-592.

Cited By

Get Citation

PDF

XML

Article views (438) PDF downloads (79)

Turn off MathJax

Article Contents

Abstract

References

Cause analysis and countermeasures of extravasation of non-chemotherapeutic drugs

Abstract

References

Catalog

Export File

Citation

Format

Content